CINCINNATI, OH--(Marketwire - Apr 19, 2011) - Medpace, Inc. today announced the addition of Dieter Seitz-Tutter as Vice President, Europe with responsibility for leading Medpace clinical operations across Western, Central, and Eastern Europe. The addition of Dr. Seitz-Tutter, along with existing clinical and support teams across the European regions, will allow Medpace to expand operations and to position the service offerings of the Medpace family of companies.
"Dr. Seitz-Tutter's extensive experience from both a clinical and management perspective make him an ideal fit for our organization," said August Troendle, MD, President and CEO, Medpace. "He will support our continued global growth and lead the operations for European markets, positioning Medpace as a strategic partner of choice for our Sponsors within the region."
Dr. Seitz-Tutter brings to the Medpace executive management team over twenty one years of business development, clinical management, and operational leadership. He is an expert in integrating both front and back-end clinical services, building effective and efficient clinical teams, and executing seamless operations to bring novel agents and therapies to market approval. Dr. Seitz-Tutter has written and published a number of scientific articles and is a frequent guest speaker within the biopharmaceutical industry, covering CRO-Sponsor partnerships, outcomes, and pricing.
Dr. Dieter Seitz-Tutter received his Doctor of Science and Master of Science degrees in biology from the Ludwig-Maximilians-University of Munich.
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.
Visit the Medpace website at www.medpace.com